An Open Label, Adaptive, Phase 1 Trial of High‐Dose Oral Nitazoxanide in Healthy Volunteers: An Antiviral Candidate for SARS‐CoV‐2-Reference-Cited by-同舟云学术

An Open Label, Adaptive, Phase 1 Trial of High‐Dose Oral Nitazoxanide in Healthy Volunteers: An Antiviral Candidate for SARS‐CoV‐2

Published:2021-11-13 Issue:3 Volume:111 Page:585-594
ISSN:0009-9236
Container-title:Clinical Pharmacology & Therapeutics
language:en
Short-container-title:Clin Pharma and Therapeutics

Author:

Walker Lauren E.¹²,FitzGerald Richard²,Saunders Geoffrey³,Lyon Rebecca²,Fisher Michael¹²^ORCID,Martin Karen³^ORCID,Eberhart Izabela³,Woods Christie²,Ewings Sean³,Hale Colin²,Rajoli Rajith K. R.¹,Else Laura¹,Dilly‐Penchala Sujan¹,Amara Alieu¹,Lalloo David G.⁴,Jacobs Michael⁴,Pertinez Henry¹,Hatchard Parys³,Waugh Robert³,Lawrence Megan³,Johnson Lucy³,Fines Keira³,Reynolds Helen¹^ORCID,Rowland Timothy²,Crook Rebecca²,Okenyi Emmanuel²,Byrne Kelly⁴^ORCID,Mozgunov Pavel⁵,Jaki Thomas⁵,Khoo Saye¹^ORCID,Owen Andrew¹^ORCID,Griffiths Gareth³,Fletcher Thomas E.²⁴,

Affiliation:

1. University of Liverpool Liverpool UK

2. Liverpool University Hospitals NHS Foundation Trust Liverpool UK

3. Southampton Clinical Trials Unit University of Southampton Southampton UK

4. Liverpool School of Tropical Medicine Liverpool UK

5. MRC Biostatistics Unit University of Cambridge Cambridge UK

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cpt.2463